Skip to main content
  • Engineering any genome, at any site, in any way

  • At the forefront of a revolutionary field offering profound benefits to human health and society

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech


Caribou Biosciences and DuPont announce strategic alliance

October 8, 2015
Caribou and DuPont cross-license CRISPR-Cas intellectual property portfolios Caribou and DuPont enter into multi-year research collaboration to advance genome editing technology platform DuPont makes equity investment in Caribou BERKELEY...

Caribou Biosciences Co-Founder Dr. Jennifer Doudna Named to TIME Magazine's TIME 100 - TIME's Annual List of the 100 Most Influential People in the World

April 16, 2015
Caribou Biosciences, a developer of CRISPR-Cas9 technologies for precision cell engineering, today announced that co-founder Jennifer Doudna, Ph.D., has been named to TIME magazine's TIME 100 - TIME's annual list of the 100 most...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...